Jeremy M. Levin, D.Phil, MB BChir, has served as our chief executive officer since March 2015 and as chairman of our board of directors since April 2014. Prior to joining us, Dr. Levin served as president and chief executive officer, of Teva Pharmaceutical Industries Ltd., a publicly held pharmaceutical company, from May 2012 to October 2013. Dr. Levin joined Teva in February 2012. From September 2007 to December 2012, Dr. Levin held several roles at Bristol-Myers Squibb Company, a publicly held pharmaceutical company, finally serving as the senior vice president of strategy, alliances and transactions. Dr. Levin also served as a member of the executive committee at Bristol-Myers Squibb Company. Prior to that, Dr. Levin served as global head of strategic alliances at Novartis Institutes for Biomedical Research, Inc., a division of Novartis AG, from 2002 to 2007. Previously, he served on the board of directors of various public and private biopharmaceutical companies, including as chairman and chief executive officer of Cadus Pharmaceuticals Corporation, a drug development company. Dr. Levin currently serves on the board of directors of BioCon Ltd., a publicly held biopharmaceutical company and Lundbeck (OMX: LUN). He has also served as a practicing physician at university hospitals in England, South Africa and Switzerland. Dr. Levin earned his B.A. in zoology, M.A. in cell biology and Ph.D. in chromatin structure, all from University of Oxford, and his MB and BChir from the University of Cambridge.
Amit Rakhit, M.D., MBA, has served as our chief medical and portfolio management officer since March 2016. Prior to joining us, Dr. Rakhit served as senior vice president, Worldwide Medical at Biogen Inc., a publicly held biotechnology company, from March 2014 to March 2016 and as vice president, program leadership & management from June 2011 to February 2014. Prior to that, he worked at Bristol-Myers Squibb Company from August 2001 to June 2011, where he most recently served as vice president, intercontinental medical. Dr. Rakhit earned his B.A. in molecular biology from the University of California, Berkeley, his M.D. from Tufts University School of Medicine, his M.S. from Vanderbilt University School of Medicine and dual MBAs from the London Business School and Columbia University. Dr. Rakhit completed his fellowship in pediatric cardiology at Harvard Medical School.
Mr. Perone joined Ovid in March 2019 and brings with him more than 20 years of legal and pharmaceutical experience. He was most recently at Celgene Corporation where for 12 years he held positions of increasing levels of responsibility most recently, as Vice President, Assistant General Counsel and Assistant Corporate Secretary. While at Celgene, Mr. Perone was responsible for corporate securities matters, transactional matters including mergers, acquisitions and licensing opportunities and contracting matters for North and South America including supporting Celgene’s clinical, manufacturing and commercial teams. Prior to joining Celgene, he was a senior legal director at ImClone Systems Inc. and began his legal career as an associate attorney at Proskauer Rose LLC in New York City. Mr. Perone received a B.Sc. in mechanical engineering from Rutgers University, an M.B.A. from Fairleigh Dickinson University and a JD with honors from Seton Hall University School of Law.
Dirk Haasner, Ph.D., M.P.M, is currently our senior vice president, global regulatory affairs, CMC, and QA. Dr. Haasner previously served as our vice president, global regulatory affairs from December 2015 to March 2016. Prior to joining us, Dr. Haasner was vice president regulatory and medical affairs, and vice president regulatory strategy and policy at Lundbeck USA, Inc., a H. Lundbeck A/S subsidiary, from February 2002 to November 2015, with responsibility for all FDA interactions on several marketed orphan drugs and all Lundbeck development compounds in psychiatry and neurology. From 1994 to 2002, Dr. Haasner was employed at F. Hoffmann-La Roche AG, a publicly held healthcare company, where he held positions of increasing responsibility in global product development and global strategic marketing before being appointed global life-cycle leader. Dr. Haasner co-founded the biotech start-up 4-Antibody AG that was acquired in 2014 by Agenus Inc., a publicly held biotechnology company. Dr. Haasner obtained a M.Sc. in molecular biology at the University of Basel, Switzerland, a Ph.D. in cell biology and immunology at the Basel Institute for Immunology, and holds a postgraduate degree in pharmaceutical medicine from the EUCOR Universities Basel, Strasbourg and Freiburg.
Timothy Daly joined Ovid in September 2015 and currently serves as treasurer and senior vice president, finance & corporate controller. Prior to joining us, Mr. Daly was vice president of finance and corporate controller at Advanced Health Media LLC from August 2013 to September 2015, a global provider of technology to healthcare professionals. From December 2011 to August 2013, Mr. Daly served as vice president, controller and chief accounting officer at Enzon Pharmaceuticals, Inc., a publicly held pharmaceuticals company. Prior to that, from 1999 to 2011, he served in various operation finance roles during his 12-year tenure at ImClone Systems Incorporated, a wholly owned subsidiary of Eli Lilly and Company, and most recently as director of finance. Mr. Daly earned his B.S. in accounting from Rider University.
Suzanne Wakamoto has been a manager for 30 years and a human resources leader for over 20. Her diverse background includes start-up, global, multi-site and non-profit organizations. She has been fortunate to work and consult in an eclectic array of industries: arts education, biotechnology, construction, entertainment, manufacturing, retail and software. Since 2008, she served as an independent HR consultant where she partnered with clients to develop more cohesive and compliant HR practices that aligned with their corporate culture and business needs. Some of her former corporate positions include: heading HR for the internationally acclaimed Blue Man Group and director of HR & administration for Cadus Pharmaceutical Corporation. Suzanne sits on the board of directors of NYC SHRM, the New York City chapter of the Society of Human Resources Management and is a founder and current chair of HR-PRO, NYC SHRM’s award winning pro-bono outreach program. She holds a Bachelor’s degree in world arts and culture from UCLA. Ultimately, Suzanne is a person who believes excellence and fun are not mutually exclusive, but rather the partnership that makes us successful every day.
Claude Nicaise, M.D., is head, strategic orphan regulatory affairs at Ovid Therapeutics. He is a respected executive with over 20 years of significant product development experience, particularly in orphan diseases.
Prior to joining Ovid, Claude was an executive vice president of clinical development and regulatory affairs at Formula Pharmaceuticals, Inc. Before that, he was senior vice president, strategic product development and global regulatory affairs at Alexion Pharmaceuticals, where he managed all regulatory activities and co-managed development programs with the head of R&D and designed, interpreted and filed all programs supporting development in rare diseases. Prior to joining Alexion, Claude served in various positions of increasing responsibility at Bristol-Myers Squibb for 24 years. Claude holds an M.D. from the Université libre de Bruxelles in Belgium.
Claude is the author of more than 60 research articles published in peer-reviewed journals and is a member of several professional medical associations, including the American Society of Clinical Oncology; the European Society for Medical Oncology; the American Society for Microbiology; and the American Society of Hematology.
Raquel has over ten years of experience across a variety of healthcare industry sectors in the US and Europe. Raquel is passionate about working with patients, clinicians, and payers at all stages of product development to address true unmet needs and ensure access.
Prior to joining Ovid, Raquel was Director of Global Market Access at GE Healthcare, based in London. In this role she led a global team responsible for market access and health economics for new product introductions from the company’s imaging technology portfolio across all therapy areas. At GE Healthcare, Raquel focused on demonstrating the value of innovative technology through research, customer partnerships, digital marketing, and sales support.
Prior to GE, Raquel was a member of Medtronic’s EMEA health economics and reimbursement team, based in Switzerland. Before joining industry, she was a neuropsychology specialist at Cogstate, a cognitive science start-up, and Columbia University Medical Center where she led operations for federally funded studies that evaluated the specificity of cognitive testing to diagnose Alzheimer’s Disease among minorities.
Raquel earned her MSc in International Health Policy and Health Economics from the London School of Economics and earned her BA in Psychology and French, cum laude, from the University of Pennsylvania. She is also a member of the University of Pennsylvania Fund executive board.
Jeannie Visootsak, M.D., M.Sc. is board-certified in general pediatrics and developmental-behavioral pediatrics with expertise in clinical-translational research specifically in pediatric and adults neurodevelopmental disorders, genetic conditions and rare diseases.
Prior to joining Ovid, Jeannie was the translational medicine leader at Roche Neuroscience where she led the global Down syndrome adult and pediatric Phase 2a and 2b clinical trials and non-interventional outcome measure studies for the development of Basmisanil (selective GABAA α5 receptor negative allosteric modulator). Prior to joining the pharmaceutical industry, Jeannie was an associate professor at Emory University School of Medicine from 2004 to 2014 and directed the Down syndrome and Fragile X syndrome centers to provide clinical care, research and education. She also provided clinical care for individuals with other developmental disabilities such as autism, genetic conditions and metabolic disorders. She has published more than 40 peer-reviewed manuscripts and book chapters, and served as a primary investigator on more than 15 Phase 1, 2 and 3 neurodevelopmental and rare diseases clinical trials. Jeannie received her M.D. from UCLA School of Medicine and M.Sc. in clinical research at Emory University.
Jeannie has also worked closely with patient advocacy groups. She co-founded the Fragile X Clinical and Research Consortium with the National Fragile X Foundation in 2005 and currently serves on the board of directors and professional advisory committee for the National Down Syndrome Congress. Jeannie has also published children’s books entitled “Fragile X Fred” and “What’s Inside You Is Inside Me, Too: My Chromosomes Make Me Unique.”
Jeremy M. Levin, D.Phil, MB BChir, has served as our chief executive officer since March 2015 and as chairman of our board of directors since April 2014. Prior to joining us, Dr. Levin served as president and chief executive officer, of Teva Pharmaceutical Industries Ltd., a publicly held pharmaceutical company, from May 2012 to October 2013. Dr. Levin joined Teva in February 2012. From September 2007 to December 2012, Dr. Levin held several roles at Bristol-Myers Squibb Company, a publicly held pharmaceutical company, finally serving as the senior vice president of strategy, alliances and transactions. Dr. Levin also served as a member of the executive committee at Bristol-Myers Squibb Company. Prior to that, Dr. Levin served as global head of strategic alliances at Novartis Institutes for Biomedical Research, Inc., a division of Novartis AG, from 2002 to 2007. Previously, he served on the board of directors of various public and private biopharmaceutical companies, including as chairman and chief executive officer of Cadus Pharmaceuticals Corporation, a drug development company. Dr. Levin currently serves on the board of directors of BioCon Ltd., a publicly held biopharmaceutical company and Lundbeck (MOX: LUN). Dr. Levin is also a serving member on the board of the Biotechnology Innovation Organization. He has also served as a practicing physician at university hospitals in England, South Africa and Switzerland. Dr. Levin earned his B.A. in zoology, M.A. in cell biology and Ph.D. in chromatin structure, all from University of Oxford, and his MB and BChir from the University of Cambridge.
Karen Bernstein, Ph.D. has served as a member of our board of directors since September 2015. Prior to joining us, Dr. Bernstein co-founded BioCentury Inc., or BioCentury, a provider of clinical, regulatory and finance news for the biotechnology and pharmaceutical industries, where she served as editor-in-chief from its inception in August 1992 to August 2015. From September 2015 to October 2016, she also served on the board of directors of Vitae Pharmaceuticals, Inc., which was acquired by Allergan Holdco US, Inc. Dr. Bernstein continues to serve as chairman of the board of directors of BioCentury. Dr. Bernstein earned her B.A. in politics and history from Brandeis University and her Ph.D. in political science from Stanford University.
Barbara Duncan, MBA, has served as a member of our board of directors since June 2017. She previously served as the chief financial officer and treasurer at Intercept Pharmaceuticals, Inc. Prior to Intercept, Ms. Duncan held various senior leadership roles of increasing responsibility at DOV Pharmaceutical, Inc., including chief financial officer and ultimately serving as chief executive officer prior to DOV’s sale to Euthymics Bioscience, Inc. in 2010. Ms. Duncan has also held roles in the corporate finance groups at SBC Warburg Dillon Read, Inc. and Lehman Brothers Inc. She currently serves on the board of Aevi Genomic Medicine, Inc., Jounce Therapeutics, Inc., Adaptimmune Therapeutics plc, Innoviva, Inc. and ObsEva SA. Ms. Duncan received her B.S. from Louisiana State University and her MBA from the Wharton School of the University of Pennsylvania.
Matthew During, M.D., D.Sc., is our founder and was appointed as our chief scientific officer in March 2015 and has served as our president and a member of our board of directors since April 2014. From April 2014 to March 2015, he served as our chief executive officer. Prior to founding our company, Dr. During founded NightstaRx Limited, a pharmaceutical company, in October 2013 and served as a consultant until November 2015. From February 2014 to December 2014, Dr. During served as a senior manager at Bridgewater Associates. Prior to that, he founded Neurologix, Inc., a pharmaceutical company, in October 1999 and served as a member of its scientific advisory board until March 2012. Dr. During also co-founded Merlin Pharmaceuticals (P) Limited, a pharmaceutical company, in February 1993 and served a member of its scientific advisory board until December 1994. Dr. During previously served on the faculty of Yale University as Professor of Neurosurgery from 1989 to 2000, as a Professor at Cornell University until 2006 and Ohio State University from 2006 to December 2014, where he currently serves as an adjunct professor. Since 2011, he has also served as a visiting professor of translational neuroscience at the University of Oxford. Dr. During earned his B.S., M.D. and D.Sc. from the University of Auckland. He also completed fellowships at Massachusetts Institute of Technology and Harvard Medical School.
Bart Friedman, J.D., has served as a member of our board of directors since November 2015. Mr. Friedman was a partner at Cahill Gordon & Reindel LLP, a New York law firm, since 1980 and became senior Ccunsel as of January 2017. Mr. Friedman’s practice focuses on corporate governance investigations and advisory and crisis advisory. Earlier in his career, Mr. Friedman worked at the Securities and Exchange Commission, initially as special counsel and later as assistant director. Mr. Friedman currently serves as chairman of the board of directors of the Sanford C. Bernstein Mutual Funds and as the lead director of the board of directors of Allied World Assurance Company Holdings, AG, a publicly held company. He currently serves as chair of the audit committee of the Brookings Institution, chair of the audit committee of Lincoln Center for the Performing Arts and treasurer of the Smithsonian’s Cooper-Hewitt Museum. Mr. Friedman earned his A.B. from Long Island University and his J.D. from Harvard Law School.
Douglas Williams, Ph.D. has served as a member of our board of directors since January 2016. Dr. Williams is currently a member on the board of directors of each of Ironwood Pharmaceuticals, Inc. and Regulus Therapeutics Inc., each a publicly held biotechnology company. Dr. Williams is president, chief executive officer and a member of the board of directors of Codiak Biosciences, Inc., a biotechnology company, which was founded in November 2015. Prior to that, he served as Biogen Inc.’s executive vice president, research and development from January 2011 to July 2015. From 2004 to 2010, Dr. Williams served in various roles at ZymoGenetics, Inc., a former publicly held pharmaceutical company, and a subsidiary of Bristol-Myers Squibb Company, a publicly held pharmaceutical company, most recently in the role of chief executive officer and a member of its board of directors. Dr. Williams also served as a member of the board of directors of each of Oncothyreon Inc. and Array BioPharma Inc. Previously, Dr. Williams held senior leadership positions within the biotechnology industry, including chief scientific officer and executive vice president of research and development at Seattle Genetics, Inc., a publicly held biotechnology company, senior vice president and Washington site leader at Amgen, Inc., a publicly held biopharmaceutical company, and executive vice president and chief technology officer at Immunex Corporation, a publicly held pharmaceutical company, which was acquired by Amgen Inc. in 2002. Dr. Williams earned his B.S. in biological sciences from the University of Massachusetts, Lowell and his Ph.D. in physiology from the State University of New York at Buffalo, Roswell Park Memorial Institute Division.
You can contact Ovid Therapeutics Board of Directors to provide comments, report concerns, or ask a question, at the following address.
Ovid Therapeutics Inc.
New York, NY 10036
You may submit your concern anonymously or confidentially by postal mail. You may also indicate whether you are a shareholder, customer, supplier or other interested party.
Communications are distributed to the Board, or to any individual director as appropriate, depending on the facts and circumstances outlined in the communication. In that regard, the Board requests that certain items that are unrelated to the duties and responsibilities of the Board be excluded, such as: